Disclaimers: The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, opinions or policies of the USUHS, HJF, the DoD or the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. Introduction: Non-small cell lung cancer (NSCLC) comprises of 85% - 90% of lung cancer, the leading cause of cancer-related deaths in the U.S. Statins, a class of commonly prescribed medications used for reducing blood cholesterol levels for cardiovascular disease prevention, have been shown with anticancer properties. However, there have been no studies examining the relationship between stain use and lung cancer survival in the Military Health System (MHS). Materials and Methods: This study was based on MilCanEpi, the linked database of the Department of Defense (DoD)’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR). The CCR collects demographic information, cancer diagnosis, tumor characteristics, cancer treatments, follow-up and vital status of MHS beneficiaries who were diagnosed or received treatments at military treatment facilities (MTFs). The MDR contains claims of inpatient, outpatient and ancillary care (including prescriptions) provided at MTFs and civilian facilities paid by the DoD. The outcome was all-cause death with follow up until death or on December 31st, 2015, the end of the study. Time-dependent Cox proportional hazard regression model was used to estimate hazard ratios (HRs) and 95% confidence interval (95% CI) comparing post-diagnosis cumulative use of statin and never use with adjustment for potential confounders. Results: Among the 5,096 patients, 864 patients used statin after NSCLC diagnosis. Compared to non-users, increased cumulative use of statin (per one-year of use) conferred a significant improved survival with adjusted HR of 0.82 (95% CI=0.75 to 0.90). In stratified analysis, the improved survival associated with cumulative use was observed among patients of age<65, age 65-79, Whites, men and women, non-active-duty patients, patients of all tumor stages, and patients who used statin both before and after NSCLC diagnosis. Conclusions: Our study suggests the survival benefit of prolonged statin use among MHS beneficiaries with NSCLC.